Company intelligence / Profile preview

Tinea Pharmaceuticals, Inc.

Palo Alto, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Tinea Pharmaceuticals developed Luliconazole cream, a topical antifungal for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis. The product was submitted to the FDA and underwent regulatory review in mid–2013. Clinical data supported efficacy for these dermatophytic infections with once-daily application regimens.[2] No recent clinical or commercial updates are available.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (topical antifungals)
Industry: Biotech

Drug pipeline

3 assets

terbinafine

Commercial

Indications: Tinea cruris, Tinea corporis

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tinea Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tinea Pharmaceuticals, Inc..

Explore the full profile